Medical Principles and Practice. 2009; 18 (5): 360-363
Dans Anglais
| IMEMR
| ID: emr-123146
ABSTRACT
The purpose of this study was to determine whether or not imatinib mesylate therapy induces growth hormone deficiency [GHD]. Seventeen patients with chronic myloid leukemia [CML] were enrolled in the study. The glucagons stimulation test [GST], and standard deviation scores [SDSs] of insulin-like growth factor 1 [IGF-I] and insulin-like growth factor binging protein [IGFBP-3] were used to determine GHD. The L-dopa test was performed on those with IGF-I SDSs above the -1.8 cut-off level. Of the 17 patients in the study, 12 [70%] had severe GHD [serum GH level<3 micro g/l after GST]. IGF-I SDSs and IGFBP-3 SDSs were below -1.8 showed insufficient GH response to L-dopa stimulation. Nine subjects [52%] had both severe GHD based on GST response and IGF-I SDS below -1.8. If an IGF-I SDS cut-off value 1<-3 were used, 5 out of 17 subjects [30%] would be classified as GH deficient. These same patients also showed severe GHD based on GST response. The data showed that a large number of patients on imatinib mesylate therapy had GH deficiency. A study involving a larger number of patients with a matched control group is needed to confirm the present observations
Recherche sur Google
Indice:
Méditerranée orientale
Sujet Principal:
Pipérazines
/
Pyrimidines
/
Facteur de croissance IGF-I
/
Glucagon
/
Lévodopa
/
Leucémie myéloïde
/
Protéine-3 de liaison aux IGF
Limites du sujet:
Femelle
/
Humains
/
Mâle
langue:
Anglais
Texte intégral:
Med. Princ. Pract.
Année:
2009
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS